BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 12115148)

  • 1. Alzheimer beta-amyloid peptides: structures of amyloid fibrils and alternate aggregation products.
    Gorman PM; Chakrabartty A
    Biopolymers; 2001; 60(5):381-94. PubMed ID: 12115148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assembling amyloid fibrils from designed structures containing a significant amyloid beta-peptide fragment.
    Tjernberg LO; Tjernberg A; Bark N; Shi Y; Ruzsicska BP; Bu Z; Thyberg J; Callaway DJ
    Biochem J; 2002 Aug; 366(Pt 1):343-51. PubMed ID: 12023906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation.
    Takahashi T; Mihara H
    Acc Chem Res; 2008 Oct; 41(10):1309-18. PubMed ID: 18937396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assembly of Alzheimer's amyloid-beta fibrils and approaches for therapeutic intervention.
    Yang DS; Serpell LC; Yip CM; McLaurin J; Chrishti MA; Horne P; Boudreau L; Kisilevsky R; Westaway D; Fraser PE
    Amyloid; 2001 Jul; 8 Suppl 1():10-9. PubMed ID: 11676284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zinc-amyloid beta interactions on a millisecond time-scale stabilize non-fibrillar Alzheimer-related species.
    Noy D; Solomonov I; Sinkevich O; Arad T; Kjaer K; Sagi I
    J Am Chem Soc; 2008 Jan; 130(4):1376-83. PubMed ID: 18179213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of beta-amyloid fibrils and its relevance to their neurotoxicity: implications for the pathogenesis of Alzheimer's disease.
    Irie K; Murakami K; Masuda Y; Morimoto A; Ohigashi H; Ohashi R; Takegoshi K; Nagao M; Shimizu T; Shirasawa T
    J Biosci Bioeng; 2005 May; 99(5):437-47. PubMed ID: 16233815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structures for amyloid fibrils.
    Makin OS; Serpell LC
    FEBS J; 2005 Dec; 272(23):5950-61. PubMed ID: 16302960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation barriers to structural transition determine deposition rates of Alzheimer's disease a beta amyloid.
    Esler WP; Felix AM; Stimson ER; Lachenmann MJ; Ghilardi JR; Lu YA; Vinters HV; Mantyh PW; Lee JP; Maggio JE
    J Struct Biol; 2000 Jun; 130(2-3):174-83. PubMed ID: 10940224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrasting in vivo effects of two peptide-based amyloid-beta protein aggregation inhibitors in a transgenic mouse model of amyloid deposition.
    Li Q; Gordon M; Etienne MA; Hammer RP; Morgan D
    Cell Transplant; 2008; 17(4):397-408. PubMed ID: 18522242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformation and fibrillogenesis of Alzheimer A beta peptides with selected substitution of charged residues.
    Fraser PE; McLachlan DR; Surewicz WK; Mizzen CA; Snow AD; Nguyen JT; Kirschner DA
    J Mol Biol; 1994 Nov; 244(1):64-73. PubMed ID: 7966323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
    van Groen T; Kiliaan AJ; Kadish I
    Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
    Güntert A; Döbeli H; Bohrmann B
    Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure and morphology of the Alzheimer's amyloid fibril.
    Stromer T; Serpell LC
    Microsc Res Tech; 2005 Jul; 67(3-4):210-7. PubMed ID: 16103997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis.
    Kirkitadze MD; Condron MM; Teplow DB
    J Mol Biol; 2001 Oct; 312(5):1103-19. PubMed ID: 11580253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging distinct conformational states of amyloid-beta fibrils in Alzheimer's disease using novel luminescent probes.
    Nilsson KP; Aslund A; Berg I; Nyström S; Konradsson P; Herland A; Inganäs O; Stabo-Eeg F; Lindgren M; Westermark GT; Lannfelt L; Nilsson LN; Hammarström P
    ACS Chem Biol; 2007 Aug; 2(8):553-60. PubMed ID: 17672509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice.
    Philipson O; Hammarström P; Nilsson KP; Portelius E; Olofsson T; Ingelsson M; Hyman BT; Blennow K; Lannfelt L; Kalimo H; Nilsson LN
    Neurobiol Aging; 2009 Sep; 30(9):1393-405. PubMed ID: 18192084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An autocatalytic reaction as a model for the kinetics of the aggregation of beta-amyloid.
    Sabaté R; Gallardo M; Estelrich J
    Biopolymers; 2003; 71(2):190-5. PubMed ID: 12767118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.
    Meredith SC
    Ann N Y Acad Sci; 2005 Dec; 1066():181-221. PubMed ID: 16533927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral immune response to fibrillar beta-amyloid peptide.
    Miller DL; Currie JR; Mehta PD; Potempska A; Hwang YW; Wegiel J
    Biochemistry; 2003 Oct; 42(40):11682-92. PubMed ID: 14529278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms initiating amyloid beta-fibril formation in Alzheimer's disease.
    Kirkitadze MD; Kowalska A
    Acta Biochim Pol; 2005; 52(2):417-23. PubMed ID: 15933761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.